Stock Taper
Guardant Health is a precision oncology company providing blood-based tests, data analytics, and research platforms for cancer detection, treatment, and clinical trial connectivity globally.

Shield™ is an FDA-approved blood-based colorectal cancer screening test utilizing AI for early detection, offering a less invasive alternative to colonoscopies and recognized as a TIME Best Invention of 2024.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Oncology | $184.4M | $189.95M ▲ | $204.95M ▲ | $219.1M ▲ |
![]() | Biopharma Data | $54.73M | $54.01M ▼ | $52.98M ▼ | $60.95M ▲ |
![]() | Screening | $24.11M | $35.13M ▲ | $41.59M ▲ | $52.87M ▲ |
![]() | Licensing Other | $1.95M | $2.18M ▲ | $2.14M ▼ | $2.06M ▼ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $249.44M | $263.55M ▲ | $284.63M ▲ | $318.04M ▲ |
![]() | NonUS | $15.76M | $17.72M ▲ | $17.04M ▼ | $16.94M ▼ |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
VTRS | $16.34 | COMPARE |
SOLV | $91.12 | COMPARE |
ASND | $247.91 | COMPARE |
BBIO | $76.60 | COMPARE |
RVTY | $128.80 | COMPARE |
ICLR | $170.02 | COMPARE |
EHC | $120.85 | COMPARE |
IONS | $61.05 | COMPARE |